miR-371a-3p Predicting Viable Tumor in Patients Undergoing RPLND for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.,The Journal of Urology

当前位置： X-MOL 学术 › J. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

miR-371a-3p Predicting Viable Tumor in Patients Undergoing RPLND for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-07-25 , DOI: 10.1097/ju.0000000000004164
Anna Thor _{1,

2} , Mette Pernille Myklebust ₃ , Anna Grenabo Bergdahl _{4,

5} , Per-Olof Lundgren _{1,

2} , Viktor Skokic _{2,

6} , Bjarte Almås ₇ , Hege Sagstuen Haugnes _{8,

9} , Torgrim Tandstad _{10,

11} , Olof Akre _{2,

6} , Gabriella Cohn-Cedermark _{12,

13} , Olav Dahl _{14,

15} , Anders Kjellman _{1,

2}

Affiliation

Division of Urology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
Mohn Cancer Research Laboratory, Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Department of Urology, Gothenburg University, Gothenburg, Sweden.
Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Department of Urology, Haukeland University Hospital, Bergen, Norway.
Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
Department of Clinical Medicine, UIT-The Arctic University of Norway, Tromsø, Norway.
The Cancer Clinic, St Olavs University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden.
Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Science, Medical Faculty, University of Bergen, Norway.

The SWENOTECA-MIR prospective multicenter study aims to assess the clinical value of miR-371a-3p as a novel marker in metastatic germ cell tumor patients undergoing retroperitoneal lymph node dissection (RPLND), to predict the presence of viable residual tumor.

中文翻译：

miR-371a-3p 预测接受 RPLND 治疗转移性睾丸癌的患者的活肿瘤：SWENOTECA-MIR 研究。

SWENOTECA-MIR 前瞻性多中心研究旨在评估 miR-371a-3p 作为新标志物在接受腹膜后淋巴结清扫术（RPLND）的转移性生殖细胞肿瘤患者中的临床价值，以预测活残留肿瘤的存在。

更新日期：2024-07-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文